Monoclonal antibodies (mAbs) are highly specific, laboratory-produced antibodies designed to target a single specific epitope or binding site on an antigen. Unlike polyclonal antibodies, which are a ...

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated ...

Could monoclonal antibodies be the key to tackling the growing problem of antimicrobial resistance? A team led by researchers at the University of Cambridge has developed a monoclonal antibody drug ...

I n 2024, the U.S. Food and Drug Administration (FDA) approved the first monoclonal antibody for reducing food allergy reactions, including anaphylaxis, in adults and children age 1 year or older. The ...

Monoclonal antibodies (mAbs) have been a key therapeutic option for non-communicable diseases for decades, and a small number of mAbs have helped treat infectious diseases, including COVID-19. The ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

In the ongoing battle against COVID-19, the United States has leaned heavily on vaccines as its primary weapon. While vaccination has been a cornerstone of the country’s public health strategy, it's ...

Data supporting antibodies is limited compared to that for authorized vaccines. Despite more than 187 million Americans being fully vaccinated against COVID-19 and data and attestations from ...

Maine faces a surge in Lyme disease cases, but hope rises as a potential antibody injection advances toward approval.

LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to ...